Clinical trial NCT00476697: UVA1 Light for Scleroderma and Similar Conditions
Official title: The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Keloid
Scleroderma
Scars
Granuloma Annulare
Acne Keloidalis Nuchae
Keywords: UVA1
scleroderma
keloids
morphea
light therapy
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2007-05-22
Enrollment: 23
Sex: ALL
Minimum age (years): 10
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this investigation is to evaluate the effectiveness of high-dose UVA1 irradiation in the treatment of fibrosing conditions of the skin, e.g., keloid (a thick scar from growth of fibrous tissue), scleroderma (deposits of fibrous tissue in the skin) and acne keloidalis nuchae (keloids on the back of the neck or hairline) old burn scars, granuloma annulare or other similar skin conditions. This UVA1 dosing schedule has been used successfully in Germany for various skin diseases, such as the above mentioned scleroderma.

Detailed description: Ultraviolet rays from the sun that reach the earth surface are divided into shorter wavelength, hence high energy, UVB (290-320nm) and longer wavelength, hence low energy UVA (320-400nm). The wavelengths of light that cause sunburn and are associated with skin cancer causation is the high energy UVB. UVA wavelengths can be further divided into relatively shorter wavelength, hence higher energy UVA2 (320-340nm) and longer wavelength, lower energy UVA1 (340-400nm). Phototherapy light boxes used in our clinic for the treatment of psoriasis, atopic dermatitis, and pruritus, as well as those used in tanning salons emit both UVB and UVA wavelengths of light. The advantages of using UVA1 light source in the treatment of skin conditions are 1) lack of skin cancer and sunburn causing rays (UVB) and 2) as a consequence, the ability to treat patients more safely and longer.

Keloid, scleroderma, acne keloidalis nuchae, and burn scars are all characterized by collagenous thickening of the skin resulting in superficial and deep cutaneous sclerosis. Treatments for these disabling conditions are inadequate at present. Recently, in non-controlled studies, UVA1 was shown to induce improvement in patients with scleroderma, granuloma annulare and urticaria pigmentosa (1-3). The mode of action of UVA1 treatment is not completely understood, however, local immuno-modulation appears to be important (4). UVA1 has also been shown to stimulate collagenase activity in a dose dependent manner in the dermis (5,6). We postulate, therefore, that UVA1 in appropriate doses can improve these fibrosing skin conditions safely through collagenase-mediated removal of excess dermal collagen.

Based on the result of this pilot study, a formal controlled clinical investigation is planned.

Eligibility criteria: Inclusion Criteria:

* Age: 10-80 years
* Clinical diagnosis of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare, and other related conditions associated with altered dermal matrix.
* No disease states or physical conditions which would impair evaluation of the test site.
* Willing and able to receive UVA1 as directed in the protocol, make evaluation visits, and follow protocol restrictions.
* Signed, written, witnessed, informed consent form.
* Must live within driving distance of Ann Arbor, Michigan.

Exclusion Criteria:

* History of photosensitivity.
* Pregnant or nursing women.
* Systemic therapy for the fibrosing skin condition within 30 days prior to study enrollment.
* Involved in an investigational study within the previous 4 weeks.

Primary outcomes:
measure: Measurement of plaque thickness, increase in mobility, plaque hardness
timeFrame: 16 weeks
Secondary outcomes:
measure: Analysis of collagen levels, mmp induction
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Department of Dermatology
state: Michigan
Study officials:
affiliation: University of Michigan hospital
name: Yolanda Helfrich, MD
role: PRINCIPAL_INVESTIGATOR
References: